Polyrizon enrolls first patient in U.S. trial of NASARIX seasonal allergy nasal spray
PLRZ•First U.S. clinical study begins
Polyrizon began its first U.S. clinical study of NASARIX (PL-14), a drug-free nasal spray for seasonal allergic rhinitis.
Results have not been presented; the trial is intended to generate future efficacy, safety, and tolerability data in patients.
The study aims to show symptom relief by creating a physical nasal barrier to reduce allergen contact.
The trial targets 120 adults across five U.S. sites, comparing NASARIX with a saline spray.
